On ECHEMI
Home > Drugs > Compound Monoammonium Glycyrrhizinate Injection

Compound Monoammonium Glycyrrhizinate Injection

Function and Efficacy

Glycyrrhizic acid monoamine has a strong affinity for steroid metabolic enzymes in the liver, thereby hindering the inactivation of cortisol and aldosterone. After use, it shows obvious corticosteroid-like effects, such as anti-inflammatory effects, anti-allergic effects, and protective membrane structures; there are no obvious corticosteroid-like adverse reactions. This product can promote monochrome metabolism, reduce the release of ALT and AST; induce γ-IFN and interleukin II, increase NK cell activity and OKT4/OKT8 ratio and activate the reticuloendothelial system; inhibit mast cell release of histamine; inhibit the formation of cell membrane phospholipase A2 (PL-A2) and prostaglandin E2 (PGE2) and granulomatous reactions; inhibit the production and formation of free radicals and lipid peroxides, and reduce the activity of proline hydroxylase; regulate calcium ion channels, protect lysosomal membranes and mitochondria

Ingredients

This product is a compound preparation, and its components are: each 1 ml contains 2 mg of monoammonium glycyrrhizinate (C42H65NO16·2H2O), 1.5 mg of L-cysteine hydrochloride (C3H7NO2S·HCl·H2O), and 20 mg of glycine (C2H5NO2).

Name Description Content CAS NO. Manufacturer
Glycyrrhizic acid ammonium saltIngredients

It has a strong affinity for steroid metabolic enzymes in the liver, thereby hindering the inactivation of cortisol and aldosterone, showing obvious corticosteroid-like effects (such as anti-inflammatory, anti-allergic and protective membrane structure), promoting monochromatic metabolism, reducing the release of ALT and AST; inducing γ-IFN and interleukin II, increasing NK cell activity and the OKT4/OKT8 ratio and activating the reticuloendothelial system; inhibiting the production and formation of free radicals and lipid peroxides, reducing the activity of proline hydroxylase; regulating calcium ion channels, protecting lysosomal membranes and mitochondria

More
53956-04-0 8
L-Cysteine hydrochloride monohydrateIngredients

Inhibits the release of histamine from mast cells; inhibits the formation of cell membrane phospholipase A2 (PL-A2) and prostaglandin E2 (PGE2) and granulomatous reaction

More
7048-04-6 4
GlycineIngredients

No specific mention of pharmacological effects

More
56-40-6 27

Indication

It is used for abnormal liver function caused by acute and chronic hepatitis; it has a certain auxiliary therapeutic effect on toxic hepatitis. It can also be used for food poisoning, drug poisoning, drug allergy, etc.

Usage and Dosage

Intravenous drip. 20-80 ml at a time, add 5% glucose or 0.9% sodium chloride 250-500 ml injection solution to dilute, and slowly drip. Once a day. Intravenous injection. 20-80 ml at a time, add an equal amount of 5% glucose injection solution, and slowly push intravenously. Once a day.

Adverse Reactions

Poor appetite, nausea, vomiting, abdominal distension, itchy skin, urticaria, dry mouth and edema, water and sodium retention, hypokalemia, pseudoaldosteronism, common headache, dizziness, palpitations and increased hypertension in the cardiovascular and cerebrovascular system. The above symptoms are generally mild and do not affect treatment. Occasionally, chest tightness, thirst and allergic reactions may occur.

Precautions

1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe hypokalemia and hypernatremia are prohibited from using this product. 3. Patients with hypertension and heart failure are prohibited from using this product. 4. Patients with renal failure are prohibited from using this product. 5. Patients with aldosteronism and tumors are prohibited from using this product.

Drug Interactions

Hypokalemia is likely to occur when used in combination with furosemide (Lasix) or thiazide diuretics.

Storage

Keep tightly closed in a cool, dark place.

Packaging Specification

20ml

Manufacturer

Anhui Changjiang Pharmaceutical Co., Ltd.

  • Founded in:

    2001-12-25
  • Address:

    No. 152, Changjiang South Road, High-tech Industrial Development Zone, Wuhu City, Anhui Province (declaration commitment)
  • Tax NO.:

    91340200733036887Q
  • Registered Funds:

    82.35294118 million yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.